Literature DB >> 24607745

The formation of tight tumor clusters affects the efficacy of cell cycle inhibitors: a hybrid model study.

Munju Kim1, Damon Reed2, Katarzyna A Rejniak3.   

Abstract

Cyclin-dependent kinases (CDKs) are vital in regulating cell cycle progression, and, thus, in highly proliferating tumor cells CDK inhibitors are gaining interest as potential anticancer agents. Clonogenic assay experiments are frequently used to determine drug efficacy against the survival and proliferation of cancer cells. While the anticancer mechanisms of drugs are usually described at the intracellular single-cell level, the experimental measurements are sampled from the entire cancer cell population. This approach may lead to discrepancies between the experimental observations and theoretical explanations of anticipated drug mechanisms. To determine how individual cell responses to drugs that inhibit CDKs affect the growth of cancer cell populations, we developed a spatially explicit hybrid agent-based model. In this model, each cell is equipped with internal cell cycle regulation mechanisms, but it is also able to interact physically with its neighbors. We model cell cycle progression, focusing on the G1 and G2/M cell cycle checkpoints, as well as on related essential components, such as CDK1, CDK2, cell size, and DNA damage. We present detailed studies of how the emergent properties (e.g., cluster formation) of an entire cell population depend on altered physical and physiological parameters. We analyze the effects of CDK1 and CKD2 inhibitors on population growth, time-dependent changes in cell cycle distributions, and the dynamic evolution of spatial cell patterns. We show that cell cycle inhibitors that cause cell arrest at different cell cycle phases are not necessarily synergistically super-additive. Finally, we demonstrate that the physical aspects of cell population growth, such as the formation of tight cell clusters versus dispersed colonies, alter the efficacy of cell cycle inhibitors, both in 2D and 3D simulations. This finding may have implications for interpreting the treatment efficacy results of in vitro experiments, in which treatment is applied before the cells can grow to produce clusters, especially because in vivo tumors, in contrast, form large masses before they are detected and treated.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Agent-based model; CDK inhibition; Cell cycle checkpoints; Cell motility; Tumor cluster

Mesh:

Substances:

Year:  2014        PMID: 24607745      PMCID: PMC5483857          DOI: 10.1016/j.jtbi.2014.02.027

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  82 in total

1.  Mathematical modeling of monoclonal conversion in the colonic crypt.

Authors:  Alexander G Fletcher; Christopher J W Breward; S Jonathan Chapman
Journal:  J Theor Biol       Date:  2012-01-23       Impact factor: 2.691

2.  The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells.

Authors:  Wei Fu; Le Ma; Baoky Chu; Xue Wang; Marilyn M Bui; Jennifer Gemmer; Soner Altiok; W Jackson Pledger
Journal:  Mol Cancer Ther       Date:  2011-04-13       Impact factor: 6.261

Review 3.  Regulation of DNA repair throughout the cell cycle.

Authors:  Dana Branzei; Marco Foiani
Journal:  Nat Rev Mol Cell Biol       Date:  2008-02-20       Impact factor: 94.444

4.  Coordination between cell growth and cell cycle transit in animal cells.

Authors:  A Zetterberg; O Larsson
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1991

Review 5.  Cyclin-dependent kinases: engines, clocks, and microprocessors.

Authors:  D O Morgan
Journal:  Annu Rev Cell Dev Biol       Date:  1997       Impact factor: 13.827

6.  A single-cell-based model of tumor growth in vitro: monolayers and spheroids.

Authors:  Dirk Drasdo; Stefan Höhme
Journal:  Phys Biol       Date:  2005-07-12       Impact factor: 2.583

7.  Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

Authors:  David Parry; Timothy Guzi; Frances Shanahan; Nicole Davis; Deepa Prabhavalkar; Derek Wiswell; Wolfgang Seghezzi; Kamil Paruch; Michael P Dwyer; Ronald Doll; Amin Nomeir; William Windsor; Thierry Fischmann; Yaolin Wang; Martin Oft; Taiying Chen; Paul Kirschmeier; Emma M Lees
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

8.  Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle.

Authors:  A Koff; A Giordano; D Desai; K Yamashita; J W Harper; S Elledge; T Nishimoto; D O Morgan; B R Franza; J M Roberts
Journal:  Science       Date:  1992-09-18       Impact factor: 47.728

9.  Visualizing spatiotemporal dynamics of multicellular cell-cycle progression.

Authors:  Asako Sakaue-Sawano; Hiroshi Kurokawa; Toshifumi Morimura; Aki Hanyu; Hiroshi Hama; Hatsuki Osawa; Saori Kashiwagi; Kiyoko Fukami; Takaki Miyata; Hiroyuki Miyoshi; Takeshi Imamura; Masaharu Ogawa; Hisao Masai; Atsushi Miyawaki
Journal:  Cell       Date:  2008-02-08       Impact factor: 41.582

10.  DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1.

Authors:  Grzegorz Ira; Achille Pellicioli; Alitukiriza Balijja; Xuan Wang; Simona Fiorani; Walter Carotenuto; Giordano Liberi; Debra Bressan; Lihong Wan; Nancy M Hollingsworth; James E Haber; Marco Foiani
Journal:  Nature       Date:  2004-10-21       Impact factor: 49.962

View more
  7 in total

Review 1.  Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues.

Authors:  Aleksandra Karolak; Dmitry A Markov; Lisa J McCawley; Katarzyna A Rejniak
Journal:  J R Soc Interface       Date:  2018-01       Impact factor: 4.118

2.  Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials.

Authors:  K A Rejniak; M C Lloyd; D R Reed; M M Bui
Journal:  Med Hypotheses       Date:  2015-06-24       Impact factor: 1.538

3.  Collective Cell Migration in a Fibrous Environment: A Hybrid Multiscale Modelling Approach.

Authors:  Szabolcs Suveges; Ibrahim Chamseddine; Katarzyna A Rejniak; Raluca Eftimie; Dumitru Trucu
Journal:  Front Appl Math Stat       Date:  2021-06-25

4.  Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy.

Authors:  Eunjung Kim; Jae-Young Kim; Matthew A Smith; Eric B Haura; Alexander R A Anderson
Journal:  PLoS Biol       Date:  2018-03-09       Impact factor: 8.029

5.  Morphophenotypic classification of tumor organoids as an indicator of drug exposure and penetration potential.

Authors:  Aleksandra Karolak; Sharan Poonja; Katarzyna A Rejniak
Journal:  PLoS Comput Biol       Date:  2019-07-16       Impact factor: 4.475

6.  Dosage and Dose Schedule Screening of Drug Combinations in Agent-Based Models Reveals Hidden Synergies.

Authors:  Lisa C Barros de Andrade E Sousa; Clemens Kühn; Katarzyna M Tyc; Edda Klipp
Journal:  Front Physiol       Date:  2016-01-06       Impact factor: 4.566

7.  Bridging cell-scale simulations and radiologic images to explain short-time intratumoral oxygen fluctuations.

Authors:  Jessica L Kingsley; James R Costello; Natarajan Raghunand; Katarzyna A Rejniak
Journal:  PLoS Comput Biol       Date:  2021-07-26       Impact factor: 4.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.